ATC Group: A02BA03 Famotidine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A02BA03 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for acid related disorders
3
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
4
H2-receptor antagonists
5
A02BA03
Famotidine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
40 mg
PAREN - Parenteral
40 mg

Active ingredients in A02BA03

Active Ingredient
Description

Famotidine is a potent competitive H2-receptor antagonist. Famotidine has a rapid onset of action and, at the recommended doses, has a long duration of action and is highly effective at relatively low blood concentrations.

Medicines in this ATC group

Drug
Countries

Tunisia

Hong Kong

Australia Hong Kong

Hong Kong

Hong Kong

Hong Kong

Turkey

Turkey

Hong Kong

Hong Kong

Hong Kong

Singapore

Hong Kong

Tunisia

Romania Turkey

Poland Turkey

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Cyprus Singapore

Hong Kong

Austria

Hong Kong

Hong Kong

Hong Kong

Singapore

Brazil

Hong Kong

Hong Kong

Hong Kong

Singapore

Hong Kong

Hong Kong

Hong Kong

Tunisia Turkey

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Canada Finland Ireland Spain United States ...

Hong Kong

Germany

Hong Kong New Zealand

Hong Kong

Lithuania Romania

Austria

Hong Kong

Hong Kong Singapore

Hong Kong

Hong Kong

Cyprus Hong Kong

Cyprus Hong Kong

Hong Kong

Austria Estonia

Tunisia

Turkey

Lithuania Poland

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Hong Kong

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
CY
Summary of Product Characteristics (SPC)
CY
Summary of Product Characteristics (SPC)
IE
Structured Product Labeling (SPL/PLR)
US
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
CY
Summary of Product Characteristics (SPC)
CY